摘要
本文报道1例患有肺腺癌的40岁女性患者,长期规律使用阿来替尼出现双下肢轻度水肿,后因病情进展更换为洛拉替尼,患者出现全身重度水肿伴张力性水泡,尤以腰部以下水肿为重,结合诊疗经过,考虑洛拉替尼加重了不良反应,同时不排除阿来替尼存在迟发性累积效应的可能。立即停药并给予对症治疗后,患者全身水肿逐渐缓解。
This article reports a case of a 40-year-old female patient with lung adenocarcinoma who developed mild bilateral lower limb edema during long-term alectinib therapy.Due to disease progression,treatment was switched to lorlatinib and the patient experienced severe systemic edema accompanied by tension blisters,particularly pronounced in the lower body.Based on the clinical course,lorlatinib was considered the primary cause of the aggravated adverse reaction,though a delayed cumulative effect of alectinib could not be entirely excluded.After immediate discontinuation of lorlatinib and symptomatic management,the patient's systemic edema gradually resolved.
作者
刘宇
黄丹
张丽容
邹剑
LIU Yu;HUANG Dan;ZHANG Li-rong;ZOU Jian(Department of Pharmacy,the People's Hospital of Pengzhou,Chengdu 611930,China;Department of oncology,the People's Hospital of Pengzhou,Chengdu 611930,China)
出处
《临床药物治疗杂志》
2025年第7期90-92,共3页
Clinical Medication Journal
